July 17 (Reuters) – Impax Laboratories Inc:
* Impax announces FDA approval of its AB rated generic
concerta® (methylphenidate hydrochloride) extended-release
* Says don’t anticipate sales of generic concerta to
meaningfully impact earnings in 2017
* Says preparing for launch including working to secure api
quota and currently expect to launch by end of this year
Source text for Eikon:
Further company coverage:
Get more stuff like this
Subscribe to our mailing list and get interesting stuff and updates to your email inbox.
Thank you for subscribing.
Something went wrong.